Centessa Pharmaceuticals (CNTA) Competitors

Centessa Pharmaceuticals has a beta of 1.13, suggesting that its share price is 13% more volatile than the broader market. Comparatively, Moderna has a beta of 1.05, suggesting that its share price is 5% more volatile than the broader market.

Centessa Pharmaceuticals has higher earnings, but lower revenue than Moderna. Centessa Pharmaceuticals is trading at a lower price-to-earnings ratio than Moderna, indicating that it is currently the more affordable of the two stocks.

Centessa Pharmaceuticals has a net margin of 0.00% compared to Moderna's net margin of -143.55%. Moderna's return on equity of -26.64% beat Centessa Pharmaceuticals' return on equity.

82.0% of Centessa Pharmaceuticals shares are owned by institutional investors. Comparatively, 75.3% of Moderna shares are owned by institutional investors. 4.1% of Centessa Pharmaceuticals shares are owned by company insiders. Comparatively, 10.8% of Moderna shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Moderna had 28 more articles in the media than Centessa Pharmaceuticals. MarketBeat recorded 33 mentions for Moderna and 5 mentions for Centessa Pharmaceuticals. Moderna's average media sentiment score of 0.65 beat Centessa Pharmaceuticals' score of 0.41 indicating that Moderna is being referred to more favorably in the news media.

Centessa Pharmaceuticals presently has a consensus price target of $40.70, indicating a potential upside of 2.78%. Moderna has a consensus price target of $35.73, indicating a potential downside of 28.58%. Given Centessa Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts clearly believe Centessa Pharmaceuticals is more favorable than Moderna.

Viatris has a beta of 0.88, meaning that its stock price is 12% less volatile than the broader market. Comparatively, Centessa Pharmaceuticals has a beta of 1.13, meaning that its stock price is 13% more volatile than the broader market.

Viatris presently has a consensus price target of $15.71, indicating a potential downside of 8.96%. Centessa Pharmaceuticals has a consensus price target of $40.70, indicating a potential upside of 2.78%. Given Centessa Pharmaceuticals' higher probable upside, analysts plainly believe Centessa Pharmaceuticals is more favorable than Viatris.

Centessa Pharmaceuticals has lower revenue, but higher earnings than Viatris. Viatris is trading at a lower price-to-earnings ratio than Centessa Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Centessa Pharmaceuticals has a net margin of 0.00% compared to Viatris' net margin of -2.04%. Viatris' return on equity of 19.04% beat Centessa Pharmaceuticals' return on equity.

79.9% of Viatris shares are owned by institutional investors. Comparatively, 82.0% of Centessa Pharmaceuticals shares are owned by institutional investors. 0.3% of Viatris shares are owned by company insiders. Comparatively, 4.1% of Centessa Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Viatris had 10 more articles in the media than Centessa Pharmaceuticals. MarketBeat recorded 15 mentions for Viatris and 5 mentions for Centessa Pharmaceuticals. Viatris' average media sentiment score of 0.64 beat Centessa Pharmaceuticals' score of 0.41 indicating that Viatris is being referred to more favorably in the media.

82.0% of Centessa Pharmaceuticals shares are held by institutional investors. Comparatively, 7.1% of Genmab A/S shares are held by institutional investors. 4.1% of Centessa Pharmaceuticals shares are held by insiders. Comparatively, 1.5% of Genmab A/S shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Centessa Pharmaceuticals currently has a consensus price target of $40.70, indicating a potential upside of 2.78%. Genmab A/S has a consensus price target of $39.07, indicating a potential upside of 45.25%. Given Genmab A/S's stronger consensus rating and higher probable upside, analysts clearly believe Genmab A/S is more favorable than Centessa Pharmaceuticals.

Centessa Pharmaceuticals has a beta of 1.13, suggesting that its share price is 13% more volatile than the broader market. Comparatively, Genmab A/S has a beta of 0.86, suggesting that its share price is 14% less volatile than the broader market.

Genmab A/S has a net margin of 21.05% compared to Centessa Pharmaceuticals' net margin of 0.00%. Genmab A/S's return on equity of 15.34% beat Centessa Pharmaceuticals' return on equity.

In the previous week, Genmab A/S had 4 more articles in the media than Centessa Pharmaceuticals. MarketBeat recorded 9 mentions for Genmab A/S and 5 mentions for Centessa Pharmaceuticals. Genmab A/S's average media sentiment score of 0.71 beat Centessa Pharmaceuticals' score of 0.41 indicating that Genmab A/S is being referred to more favorably in the news media.

Genmab A/S has higher revenue and earnings than Centessa Pharmaceuticals. Centessa Pharmaceuticals is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

82.0% of Centessa Pharmaceuticals shares are held by institutional investors. 4.1% of Centessa Pharmaceuticals shares are held by insiders. Comparatively, 40.0% of Ascendis Pharma A/S shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Centessa Pharmaceuticals currently has a consensus price target of $40.70, indicating a potential upside of 2.78%. Ascendis Pharma A/S has a consensus price target of $291.50, indicating a potential upside of 18.74%. Given Ascendis Pharma A/S's stronger consensus rating and higher probable upside, analysts clearly believe Ascendis Pharma A/S is more favorable than Centessa Pharmaceuticals.

Centessa Pharmaceuticals has a beta of 1.13, suggesting that its share price is 13% more volatile than the broader market. Comparatively, Ascendis Pharma A/S has a beta of 0.41, suggesting that its share price is 59% less volatile than the broader market.

Ascendis Pharma A/S has a net margin of 57.87% compared to Centessa Pharmaceuticals' net margin of 0.00%. Ascendis Pharma A/S's return on equity of 0.00% beat Centessa Pharmaceuticals' return on equity.

In the previous week, Ascendis Pharma A/S had 5 more articles in the media than Centessa Pharmaceuticals. MarketBeat recorded 10 mentions for Ascendis Pharma A/S and 5 mentions for Centessa Pharmaceuticals. Ascendis Pharma A/S's average media sentiment score of 0.96 beat Centessa Pharmaceuticals' score of 0.41 indicating that Ascendis Pharma A/S is being referred to more favorably in the news media.

Centessa Pharmaceuticals has higher earnings, but lower revenue than Ascendis Pharma A/S. Centessa Pharmaceuticals is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks.